Clinical Trial Update: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating intravesical Nadofaragene Firadenovec versus observation in participants with intermediate-risk non-muscle invasive bladder cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Nadofaragene firadenovec (nadofaragene firadenovec)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Status: RECRUITING